We hereby inform you that the Board of Directors in their meeting held on May 29, 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditor's ....
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bafna Pharmaceuticals reported total income of INR 15,537.37 Lakhs for FY26 vs INR 14,559.92 Lakhs in FY25 (approx. 6.7% growth). Revenue from Operations stood at INR 14,559.92 Lakhs. Profit before Tax surged to INR 1,097.02 Lakhs vs INR 415.25 Lakhs in the prior year (+164%). PAT more than tripled to INR 460.88 Lakhs from INR 153.50 Lakhs. EBITDA expanded significantly year-on-year. Operating cash flow remained positive at INR 1,537.08 Lakhs. The auditor (Brahmayya & Co.) issued an unmodified (clean) opinion with an Emphasis of Matter on GST disputes totalling INR 566.56 Lakhs (INR 235.47 Lakhs demand + INR 331.09 Lakhs refund recovery), which the company is contesting via appeal/writ petition.
Strong bottom-line growth with PAT tripling reflects improved profitability and margin expansion. However, the unresolved GST demand of INR 566.56 Lakhs remains a contingent liability risk. No going concern issues, and the clean audit opinion supports financial reliability.